Literature DB >> 22006565

Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis.

Deyan Luo1, Frank M Szaba, Lawrence W Kummer, Lawrence L Johnson, Erik I Tucker, Andras Gruber, David Gailani, Stephen T Smiley.   

Abstract

In mice infected sublethally with Listeria monocytogenes, fibrin is deposited at low levels within hepatic tissue, where it functions protectively by limiting bacterial growth and suppressing hemorrhagic pathology. Here we demonstrate that mice infected with lethal doses of L. monocytogenes produce higher levels of fibrin and display evidence of systemic coagulopathy (i.e., thrombocytopenia, fibrinogen depletion, and elevated levels of thrombin-antithrombin complexes). When the hepatic bacterial burden exceeds 1×10(6) CFU, levels of hepatic fibrin correlate with the bacterial burden, which also correlates with levels of hepatic mRNA encoding the hemostatic enzyme factor XI (FXI). Gene-targeted FXI-deficient mice show significantly improved survival upon challenge with high doses of L. monocytogenes and also display reduced levels of hepatic fibrin, decreased evidence of coagulopathy, and diminished cytokine production (interleukin-6 [IL-6] and IL-10). While fibrin limits the bacterial burden during sublethal listeriosis in wild-type mice, FXI-deficient mice display a significantly improved capacity to restrain the bacterial burden during lethal listeriosis despite their reduced fibrin levels. They also show less evidence of hepatic necrosis. In conjunction with suboptimal antibiotic therapy, FXI-specific monoclonal antibody 14E11 improves survival when administered therapeutically to wild-type mice challenged with high doses of L. monocytogenes. Together, these findings demonstrate the utility of murine listeriosis as a model for dissecting qualitative differences between protective and pathological host responses and reveal novel roles for FXI in exacerbating inflammation and pathogen burden during a lethal bacterial infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22006565      PMCID: PMC3255681          DOI: 10.1128/IAI.05568-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever.

Authors:  E C van Gorp; M C Minnema; C Suharti; A T Mairuhu; D P Brandjes; H ten Cate; C E Hack; J C Meijers
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

Review 3.  Human recombinant activated protein C for severe sepsis.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation.

Authors:  R F Franco; E de Jonge; P E Dekkers; J J Timmerman; C A Spek; S J van Deventer; P van Deursen; L van Kerkhoff; B van Gemen; H ten Cate; T van der Poll; P H Reitsma
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

Review 6.  Listeria monocytogenes: clinical and experimental update.

Authors:  Edward J Wing; Stephen H Gregory
Journal:  J Infect Dis       Date:  2002-02-15       Impact factor: 5.226

7.  Activation of endothelial cell protease activated receptor 1 by the protein C pathway.

Authors:  Matthias Riewald; Ramona J Petrovan; Aaron Donner; Barbara M Mueller; Wolfram Ruf
Journal:  Science       Date:  2002-06-07       Impact factor: 47.728

Review 8.  The enigma of sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Peter A Ward
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Fibrin-mediated protection against infection-stimulated immunopathology.

Authors:  Lawrence L Johnson; Kiera N Berggren; Frank M Szaba; Wangxue Chen; Stephen T Smiley
Journal:  J Exp Med       Date:  2003-03-10       Impact factor: 14.307

10.  Coagulation in sepsis: all bugs bite equally.

Authors:  Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2004-02-10       Impact factor: 9.097

View more
  20 in total

1.  Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death.

Authors:  Robert Silasi; Ravi Shankar Keshari; Cristina Lupu; Walter Janse Van Rensburg; Hala Chaaban; Girija Regmi; Aleksandr Shamanaev; Joseph J Shatzel; Cristina Puy; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Owen J T McCarty; Florea Lupu
Journal:  Blood Adv       Date:  2019-02-26

Review 2.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

Review 3.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

4.  Factor XI and pulmonary infections.

Authors:  D Gailani; B M Mohammed; Q Cheng
Journal:  Haemophilia       Date:  2018-05-29       Impact factor: 4.287

5.  Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H.

Authors:  Cristina Puy; Jiaqing Pang; Stéphanie E Reitsma; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Florea Lupu; Owen J T McCarty
Journal:  J Immunol       Date:  2021-04-15       Impact factor: 5.422

Review 6.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 7.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

8.  Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Authors:  Christina U Lorentz; Norah G Verbout; Michael Wallisch; Matthew W Hagen; Joseph J Shatzel; Sven R Olson; Cristina Puy; Monica T Hinds; Owen J T McCarty; David Gailani; András Gruber; Erik I Tucker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

9.  Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.

Authors:  Reut Shnerb Ganor; Dror Harats; Ginette Schiby; David Gailani; Hanna Levkovitz; Camila Avivi; Ilia Tamarin; Aviv Shaish; Ophira Salomon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-21       Impact factor: 8.311

Review 10.  Factor XIa inhibitors: A review of the patent literature.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.